Kuur Therapeutics Announces First Patients Dosed with Allogeneic CAR-NKT Cell Therapy
by -
Allogeneic “off-the-shelf” chimeric antigen receptor-natural killer T cell (CAR-NKT) therapy platform could overcome many of the challenges of current autologous CAR-T therapies
-
The CAR-NKT cell platform has tumor-homing properties and is unlikely to cause GvHD
-
Phase 1 ANCHOR clinical study will enroll adult patients with relapsed/refractory (R/R) CD19 positive malignancies
Kuur Therapeutics, a leader in the development of off-the-shelf CAR-NKT cell immunotherapies for the treatment of hematological and solid malignancies, today announced the treatment of the first patients in its ANCHOR phase 1 study of KUR-502, an allogeneic CAR-NKT therapy.
“This is an important day, as the initiation and dosing of the first patients in the ANCHOR phase 1 clinical study marks the first time that patients have been treated with an allogeneic engineered CAR-NKT cell therapy,” said Dr. Carlos Ramos, Principal Investigator of the ANCHOR study, Professor of Medicine in the Center for Cell and Gene Therapy (CAGT) at